Real-world data of China: Analysis of HPV vaccine coverage and post-vaccination adverse reaction monitoring in Western Chinese provinces from 2018 to 2021

Figures & data

Table 1. HPV vaccination doses of different types in Gansu Province from 2018 to 2021.

Type	1st Dose	2nd Dose	3rd Dose	Total^1
2-valent HPV (Adsorbed Vaccine)	31,609	21,422	4,253	57,284
2-valent HPV (E. coli)	9,699	9,165	7,171	26,035
4-valent HPV (S. cerevisiae)	41,920	36,101	30,301	108,322
9-valent HPV (S. cerevisiae)	24,697	20,709	16,712	62,118
Total^Citation2	107,925	87,397	58,437	253,759

Total^1: Total doses administered for the same vaccine type.

Total^2: Total doses administered for different vaccine types per dose.

Figure 1. HPV vaccine first dose coverage (%) among 9–45 year-old females in different regions of Gansu Province, 2018–2021.

Figure 2. Gansu province first dose HPV vaccine coverage rates (%) in Different Age Groups, 2018–2021.

Figure 3. Composition of first dose HPV vaccination numbers among women in different occupations in Gansu Province from 2018 to 2021.

Table 2. Adverse reaction reports of HPV vaccination in different age groups in Gansu Province from 2018 to 2021 (reported rate: per 100,000).

Age	Vaccine doses administered	AEFI		Common Adverse Reaction		Rare Adverse Reaction
		Case	Reporting Rate (%)	Case	Reporting Rate (%)	Case	Reporting Rate (%)
Age 9–18*	5,147	4	77.72	4	77.72	–	–
Age 19–45	248,612	29	11.66	26	10.46	1	0.40
Total	253,759	33	13.00	30	11.82	1	0.39

*Ages 9–14 received only 3 doses, combined and grouped together with ages 15–18 for statistical purposes.

Table 3. Adverse reaction reporting for different types of HPV vaccines in Gansu Province from 2018 to 2021 (reporting rate: per 100,000).

Type	Number of Different Types of Vaccines Administered	AEFI		Common Adverse Reaction		Rare Adverse Reaction
		Case	Reporting Rate (%)	Case	Reporting Rate (%)	Case	Reporting Rate (%)
HPV2 (Adsorbed Vaccine)	57,284	5	8.73	5	8.73	–	–
HPV2 (E. coli)	26,035	2	7.68	2	7.68	–	–
HPV4 (S. cerevisiae)	108,322	13	12.00	10	9.23	1	0.92
HPV9 (S. cerevisiae)	62,118	13	20.93	13	20.93	–	–
Total	253,759	33	13.00	30	11.82	1	0.39

Table 4. Adverse reaction reports of different doses of HPV vaccination in Gansu Province from 2018 to 2021 (reported incidence rate: per 100,000).

Type	Common Adverse Reaction						Rare Adverse Reaction
	1st Dose		2nd Dose		3rd Dose		1st Dose
	Case	Reporting Rate (%)	Case	Reporting Rate (%)	Case	Reporting Rate (%)
HPV2 (Adsorbed Vaccine)	4	12.65	–	–	1	23.51	–
HPV2 (E. coli)	1	10.31	1	10.91	–	–	–
HPV4 (S. cerevisiae)	8	19.08	2	5.54	–	–	1
HPV9 (S. cerevisiae)	6	24.29	–	–	7	41.89	–
Total	19	17.60	3	3.43	8	13.69	1

Table 5. The occurrence of adverse reactions after receiving different types of HPV vaccines (reported incidence: 1 per 100,000).

Adverse Reactions	HPV2 (Adsorbed Vaccine)		HPV2 (E. coli)		HPV4 (S. cerevisiae)		HPV9 (S. cerevisiae)		Total
	Case	Reporting Rate (%)	Case	Reporting Rate (%)	Case	Reporting Rate (%)	Case	Reporting Rate (%)	Case	Reporting Rate (%)
Common Adverse Reaction
Fever (Axillary °C)	4	6.98	–	–	2	1.85	8	12.88	14	5.52
37.1~	2	3.49	–	–	–	–	–	–	2	0.79
37.6~	2	3.49	–	–	1	0.92	1	1.61	4	1.58
≥38.6	–	–	–	–	1	0.92	7	11.27	8	3.15
Swelling (Diameter cm)	–	–	1	3.84	3	2.77	5	8.05	9	3.55
≤2.5	–	–	–	–	2	1.85	–	–	2	0.79
2.6~	–	–	–	–	–	–	4	6.44	4	1.58
>5.0	–	–	1	3.84	1	0.92	1	1.61	3	1.18
Lump (Diameter cm)	–	–	1	3.84	–	–	4	6.44	5	1.97
≤2.5	–	–	1	3.84	–	–	–	–	1	0.39
2.6~	–	–	–	–	–	–	3	4.83	3	1.18
>5.0	–	–	–	–	–	–	1	1.61	1	0.39
Headache	2	3.49	–	–	2	1.85	3	4.83	7	2.76
N/V	1	1.75	1	3.84	3	2.77	1	1.61	5	1.97
Muscle Pain	1	1.75	–	–	2	1.85	1	1.61	4	1.58
Fatigue	2	3.49	–	–	4	3.69	2	3.22	8	3.15
Skin Rash	–	–	–	–	1	0.92	1	1.61	2	0.79
Vaginal Bleeding	1	1.75	–	–	–	–	–	–	1	0.39
Rare Adverse Reaction
Non-Cardiogenic Chest Pain	–	–	–	–	1	0.92	–	–	1	0.39

N/V: Nausea/Vomiting.

Table 6. Adverse reactions at different time intervals after vaccination with different types of HPV vaccines (reported incidence: 1 per 100,000).

Time Interval	HPV2 (Adsorbed Vaccine)		HPV2 (E. coli)		HPV4 (S. cerevisiae)		HPV9 (S. cerevisiae)		Total
	Case	Composition (%)	Case	Composition (%)	Case	Composition (%)	Case	Composition (%)	Case	Composition (%)
<1 day	3	60.00	2	100.00	7	63.64	9	69.23	21	67.74
1 day ~	2	40.00	–	–	4	36.36	2	15.38	8	25.81
3 days ~	–	–	–	–	–	–	1	7.69	1	3.23
7 days ~	–	–	–	–	–	–	1	7.69	1	3.23
Total	5	100.00	2	100.00	11	100.00	13	100.00	31	100.00

Wanqing C, Rongshou Z, BP D, Siwei Z, Hongmei Z, Freddie B, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016:115–32. doi:10.3322/caac.21338.

 PubMed Web of Science ®Google Scholar

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–9. doi:10.3322/caac.21492.

 PubMed Web of Science ®Google Scholar